Dasatinib-Blinatumomab for Ph-Positive ALL. Reply

N Engl J Med. 2021 Jan 28;384(4):384. doi: 10.1056/NEJMc2033785.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Bispecific*
  • Dasatinib
  • Humans
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma*

Substances

  • Antibodies, Bispecific
  • blinatumomab
  • Dasatinib